Pain during sex is one of the most common and least-discussed symptoms of menopause. Many women quietly stop having sex altogether, or push through discomfort they were told to expect, without ever being told that effective, evidence-based treatment exists. If something that used to feel good has started to feel sharp, burning, or simply wrong, that is not just aging. It is a clinical condition with a name, a mechanism, and treatments that work.
The medical term is dyspareunia, meaning painful intercourse, and it affects a significant portion of women after menopause. Estimates suggest it impacts roughly half of postmenopausal women to some degree, yet fewer than a quarter ever bring it up with a clinician. The gap between how many women experience it and how many receive care is one of the quiet failures of standard midlife health practice.
You deserve a direct answer to a direct problem. Here is what is actually happening, why it happens, and what your options are.
Why Menopause Makes Sex Painful
The underlying cause in most postmenopausal women is estrogen loss. Estrogen is what keeps vaginal tissue supple, thick, and well-lubricated. When estrogen levels fall sharply after menopause, the vaginal walls gradually thin, lose elasticity, and produce less natural moisture. The technical term for this cluster of changes is genitourinary syndrome of menopause, or GSM. It replaced the older term "atrophic vaginitis" because doctors recognized that the changes affect not just the vagina but also the vulva, urethra, and bladder.
Unlike hot flashes, which often ease over time on their own, GSM tends to worsen without treatment. The tissue changes are progressive. This matters because women sometimes wait, hoping things will improve naturally, and the discomfort deepens instead. Penetration becomes painful. Friction that was once pleasurable causes micro-tears. The body learns to anticipate pain, which triggers muscle guarding, another layer of physical tension that compounds the problem.
Other factors can contribute alongside estrogen loss. Testosterone, which also declines through perimenopause and menopause, plays a role in tissue health and sensation. Reduced blood flow to the genital area, pelvic floor changes, certain medications (particularly some antidepressants and antihistamines), and even chronic stress can all layer onto the hormonal shift. Pinpointing what is driving the pain in your specific situation matters, because treatment is more precise when it addresses the actual cause rather than a generic symptom.
What Dyspareunia Actually Feels Like
Pain with sex after menopause does not always look the same from one woman to another. Some women describe a burning sensation at penetration. Others feel a deep aching during or after intercourse. Some notice that what used to require no effort now requires significant arousal time just to be comfortable, and even then does not feel right. Spotting or light bleeding after sex is another common sign of tissue fragility from estrogen loss.
There can also be pain in situations that have nothing to do with a partner. Inserting a tampon, a gynecological speculum, or even wearing tight clothing can feel uncomfortable. Urinary symptoms often accompany these changes too: increased urgency, recurrent urinary tract infections, and a burning sensation when urinating. These are all part of the same genitourinary syndrome, driven by the same hormonal shifts.
Pain during sex after menopause is not a relationship problem or a psychological failing. It is a tissue problem with a hormonal cause, and it responds well to the right clinical treatment.
The emotional weight of this symptom is real. Many women feel shame about bringing it up, worry that something is seriously wrong, or grieve the loss of a part of their life that mattered to them. Those feelings are valid. They are also a reason not to wait: this is one of the more responsive symptom clusters in menopause medicine, with several well-studied treatment options available.
Treatment Options That Are Evidence-Based
Treatment for dyspareunia related to GSM generally falls into a few categories, and for many women, more than one approach works together. A physician evaluation is the starting point, because the right treatment depends on the cause, the severity, and your full health picture.
Local Estrogen Therapy
For women whose primary driver is vaginal estrogen loss, low-dose local estrogen therapy is the most well-supported first-line treatment in the clinical literature. Local estrogen comes in several forms: vaginal creams, suppositories, tablets (vaginal inserts), and a flexible ring placed inside the vagina. All deliver estrogen directly to the vaginal tissue with very limited systemic absorption, which makes them an option for many women who cannot or prefer not to take systemic hormone therapy.
The effect is tissue-level: the vaginal walls regain thickness and elasticity over weeks of regular use, natural lubrication improves, and the pH of the vaginal environment normalizes. Most women begin to notice a difference within four to eight weeks, with continued improvement over three to six months of use. This is not a short-term fix but a sustained change in tissue health.
Systemic Hormone Therapy
For women who are also managing hot flashes, sleep disruption, mood changes, or other systemic menopause symptoms alongside painful sex, systemic hormone therapy for women addresses both the whole-body and the local symptoms. Systemic estrogen therapy, often combined with progesterone in women with a uterus, raises circulating estrogen levels and benefits vaginal tissue along with the rest of the body. The decision to use systemic therapy involves a thorough review of your health history, which is why physician-led evaluation is the right starting point rather than self-directing treatment.
The picture around hormone therapy has shifted considerably from the oversimplified safety scares of the early 2000s. Current evidence, interpreted by physicians who specialize in this area, distinguishes clearly between different hormones, routes of delivery, timing of initiation, and individual patient profiles. For women in their 40s and 50s who are within a reasonable window from the onset of menopause, the benefit-to-risk profile for systemic hormone therapy is generally favorable when properly evaluated.
Non-Hormonal Options
Some women cannot use estrogen-based therapies due to certain health histories, or prefer to start with non-hormonal approaches. Several options have meaningful clinical evidence behind them. Ospemifene is an oral selective estrogen receptor modulator (SERM) approved specifically for dyspareunia in postmenopausal women. Vaginal moisturizers, used regularly rather than only at the time of sex, help maintain tissue hydration and pH balance over time. These are distinct from lubricants, which provide temporary comfort but do not address the underlying tissue changes.
Pelvic floor physical therapy is another underused resource. When dyspareunia has been ongoing, the body's protective muscle guarding can persist even after the tissue is treated with estrogen. A pelvic floor therapist can address that layer of the problem. Some women benefit from both hormone treatment and pelvic floor therapy running in parallel.
Why This Symptom So Often Goes Untreated
Stigma is the first barrier. Many women grew up in a culture that treated sexual discomfort as something private, something to endure quietly, or something not worth taking up a doctor's appointment for. That conditioning runs deep. Even in an appointment focused on menopause, many women do not bring up painful sex, and many clinicians do not ask.
Time is the second barrier. A standard primary care appointment rarely allows the kind of conversation that painful intercourse requires. Describing the symptom, understanding what is driving it, reviewing the treatment landscape, and making a shared decision about care all take longer than 10 or 12 minutes. The conversation gets skipped, and the symptom continues.
A third barrier is the belief that nothing can really be done. Some women have been told this directly, or have absorbed it indirectly. That belief is inaccurate. Dyspareunia related to GSM is one of the most treatable conditions in menopause medicine. Women who receive appropriate care, whether local estrogen, systemic hormone therapy, non-hormonal treatments, or some combination, report meaningful improvements in comfort, intimacy, and quality of life. The evidence is there. The gap is in accessing care that actually delivers it.
The Connection to Broader Sexual and Hormonal Health
Dyspareunia rarely arrives in isolation. Many women dealing with painful sex are also experiencing changes in desire, arousal, or sensation. Low libido and painful sex often share hormonal roots: estrogen and testosterone both contribute to genital tissue health, natural lubrication, and the neurological pathways underlying arousal. Treating the pain without addressing desire, or the other way around, often leaves women feeling only partially helped.
If you have read about low libido in menopause and recognized yourself there, it is worth knowing that the two symptoms may be linked at the hormonal level. A clinical evaluation that looks at both through comprehensive hormone testing is more likely to produce a care plan that addresses how you actually feel, rather than one symptom at a time.
Sleep disruption and mood changes also interact with sexual health in ways that are easy to underestimate. Chronic poor sleep blunts desire and increases pain sensitivity. If sleep disruption is part of your picture, it is worth mentioning alongside the sexual symptoms during your clinical consultation. A physician who sees the full pattern has a better chance of building a care plan that works across all of it.
How WomenKind Approaches This
At WomenKind, women's sexual health is a core part of the care model, not an afterthought. Dr. Joseph Urban brings board-certified, physician-led evaluation to each consultation, starting with a 90-minute initial visit built to understand your full hormonal picture before any treatment recommendations are made. That includes comprehensive hormone testing, a review of your symptoms across all systems, and the kind of unhurried conversation where something like painful sex can actually be discussed with the specificity it deserves.
Care through WomenKind is delivered via telehealth, which means you can have that initial conversation from home, without the discomfort of describing intimate symptoms in a waiting room. Ongoing membership includes unlimited messaging with the care team, so questions that come up between visits, or changes in how treatment is working, can be addressed without scheduling a new appointment. It also removes one of the real logistical barriers to this kind of care: geography. WomenKind is licensed to provide perimenopause and menopause care in all 50 states.
If you want to understand how the care model works before committing, the how care works page walks through the process from first contact to ongoing care plan. When you are ready to start, a medical consultation is the first step.
Pain with sex is not a small complaint, and it is not something to keep adjusting to. A physician who listens carefully and has the right clinical tools can make a real and lasting difference. That kind of care is available to you.
